Medical/Pharmaceuticals

GRIT Bio Appoints Jie Jia, Ph.D., as Chief Operating Officer

SHENZHEN, China, Jan. 3, 2025 /PRNewswire/ -- Shenzhen GRIT Biotechnology Co., Ltd., a leading company in cell therapy globally, today announced the appointment ofJie Jia, Ph.D., as Chief Operating Officer (COO), effective on the date of this press release. Dr. Jia, Jie brings over 20 years of...

2025-01-03 15:30

Nona Biosciences Announces Update on Its Collaborator DualityBio's Antibody-Drug Conjugate (ADC) Collaboration with BeiGene

CAMBRIDGE, Mass., Jan. 3, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), today announced that BeiGene. Ltd. has exercised its exclusive option to acquire global development, manufacturing, and commercialization right...

2025-01-03 13:30 446

Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration

SAN FRANCISCO and SUZHOU, China, Jan. 3, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...

2025-01-03 08:00 1342

CathWorks Announces the Completion of Enrollment for Landmark ALL-RISE Randomized Controlled Trial

ALL-RISE Study Included Over 1,924 Patients in 59 Sites Across  North America, Asia, Europe and the Middle East NEWPORT BEACH, Calif., Jan. 3, 2025 /PRNewswire/ -- CathWorks, a global leader in medical device digital health innovations, announced today the successful completion of enrollment of t...

2025-01-03 02:30 831

Hanx Biopharmaceuticals, Ltd. Announces First Patient Dosing in First-in-Human Phase 1 Clinical Trial of HX044

WUHAN, China, Jan. 2, 2025 /PRNewswire/ -- Hanx Biopharmaceuticals, CO. Ltd, an innovative biotechnology company developing next-generation immunotherapies to address the challenges of unmet medical need diseases, today announced the first patient dosing inAustralia on Dec 30, 2024 for Phase 1 cl...

2025-01-03 01:43 1441

PieX AI: Launching the World's First Personalized, On-device AI Pendant at CES 2025

NEW YORK, Jan. 2, 2025 /PRNewswire/ -- PieX AI , a global leader in multimodal AI hardware for smart health, is set to proudly launch the world's first pendant featuring personalized, on-device AI at CES 2025. This innovative product aims to revolutionize mental health management...

2025-01-02 21:00 1605

HKSH Symposium on Advances in Cancer Management 2024 Breakthroughs in Cancer Management

HONG KONG, Jan. 2, 2025 /PRNewswire/ -- HKSH Cancer Centre organised the sixth "HKSH Symposium on Advances in Cancer Management" ("The Symposium") which was held on12 December 2024 at the HKSH Eastern Building. With the theme "Breakthroughs in Cancer Management", the Symposium attracted approxima...

2025-01-02 17:50 1627

Fapon Biopharma Introduces FP008 at Biotech Showcase: A Safer and More Effective Immunotherapy for Refractory Cancers

SAN FRANCISCO, Jan. 2, 2025 /PRNewswire/ -- Fapon Biopharma, an innovator in developing therapeutic antibodies and fusion proteins, will present its latest breakthrough immunocytokine, FP008, onJan 14, 2025, at the Biotech Showcase investor conference, following J.P. Morgan Healthcare Week. This ...

2025-01-02 17:17 807

FDA Grants Orphan Drug Designation to MicuRx's MRX-5 for NTM Infections

SHANGHAI, Jan. 1, 2025 /PRNewswire/ -- Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx",688373.SH) announced that MRX-5, its self-developed anti-infection drug, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment ofnon-tuberculous myco...

2025-01-02 12:52 1437

HEALTH IN YOUR HANDS

The Rise of Home Testing for a Safer Future with AwarerHOME™ KUALA LUMPUR, Malaysia, Jan. 2, 2025 /PRNewswire/ -- HIV remains one of the most pressing health issues globally, yet for many, the conversation around it is still surrounded by discomfort and stigma. Despite advances in treatment and ...

2025-01-02 11:20 1396

Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate

SAN FRANCISCO and SUZHOU, China, Jan. 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...

2025-01-02 07:30 3669

CARsgen Announces the Initiation of an Investigator-Initiated Trial for an Allogeneic CD19/CD20 CAR-T Therapy

SHANGHAI, Dec. 31, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the initiation of an investigator-initiated trial (IIT) inChina for K...

2024-12-31 21:50 2622

Ractigen Therapeutics Founder Dr. Long-Cheng Li Awarded 2024 Life Science Ice Breaking Award

NANTONG and SUZHOU, China, Dec. 31, 2024 /PRNewswire/ -- Ractigen Therapeutics proudly announces that its Founder and CEO, Dr.Long-Cheng Li, has been honored with the 2024 Life Science Ice Breaking Award. This award, established by Mr. Cai Lei, a prominent ALS patient and advocate, along with his ...

2024-12-31 20:00 1702

CG MedTech and CGBIO Showcase Korea's Spine Surgery Excellence to Global Experts

SEOUL, South Korea, Dec. 31, 2024 /PRNewswire/ -- CG MedTech (f/k/a Innosys, CEO Ju Mi Chung), a leading Korean orthopedic implant research and manufacturing company, partnered withCGBIO to host the International Spine Endoscopy Training Course. The event welcomed 12 medical professionals from nin...

2024-12-31 20:00 1502

Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study

Further secures Brii's rights in BRII-179 with full control of intellectual property, future manufacturing and supply Several combination treatment studies containing BRII-179 have quickly started to carry forward the Company's strategy for HBV functional cure DURHAM, N.C. and BEIJING, Dec. 31, ...

2024-12-31 19:10 3092

Ping An Health Supported the Official Release of the "Group Standards for Remote and Internet-Based Family Doctor Healthcare Services"

HONG KONG and SHANGHAI, Dec. 31, 2024 /PRNewswire/ -- With Ping An Healthcare and Technology Company Limited's ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) strategic support, and guidance from the General Practice Development Research Center of Peking Universit...

2024-12-31 15:26 2427

Duality Biologics Announces B7H4 ADC Milestone Achievement and License Exercise by BeiGene

SOMERSET, N.J., SHANGHAI and SUZHOU, China, Dec. 30, 2024 /PRNewswire/ -- Duality Biologics ("DualityBio") announced that, BeiGene. Ltd. has exercised its exclusive option for the B7H4 antibody-drug conjugate (ADC) DB1312/BG-C9074 from DualityBio, securing global development, manufacturing, and ...

2024-12-31 08:00 1472

NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports

MELBOURNE, Australia and BRUSSELS, Dec. 31, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) and the Brussels-based Oncidium foundation today announce that results for the NOBLE Registry of TLX599-CDx (99mTc-iPSMA) have been published in the European ...

2024-12-31 04:45 2239

I Peace manufactures 100 lines of GMP iPS Cells cumulatively

Proof of customer recognition of its quality and mass manufacturing capability PALO ALTO, Calif., Dec. 30, 2024 /PRNewswire/ -- Leading GMP cell CDMO I Peace, Inc. (https://ipeace.com/en/ ), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell ther...

2024-12-31 04:24 934

Bridge Biotherapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SEONGNAM, South Korea and BOSTON, Dec. 30, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis and cancer, today announced that James Jungkue Lee, Founder and CEO of Bridge Biotherapeutics, will present ...

2024-12-30 23:00 1997
12345 ... 617